Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Mears chairman picks up shares, Croda secretary involved in sale-and-purchase

(Sharecast News) - Mears Group was among those on the list of director purchases on Tuesday, after its chairman picked up a large tranche of shares. The company said Jim Clarke bought 30,000 shares on 11 September, in a single transaction on the main market of the London Stock Exchange.

Clarke paid 275.64p for each share, valuing the transaction at a total of £82,692.00.

Following the purchase, Mears said Jim Clarke had an interest in 30,000 shares, representing about 0.03% of its voting share capital.

Croda International was also on the list of director transactions, after its company secretary and a close associate were involved in a pair of sale and purchase transactions.

The firm said the secretary Thomas Brophy, and a person closely associated with them, Sarah Brophy, both sold large tranches of shares in the company and purchased back a small amount.

Its disclosure said each of the Brophys sold 2,250 shares for 5,157.83p each, valuing both sales at £116,051.18.

They then each purchased back 384 shares for the same price, giving that side of the transactions a respective value of £19,806.07 each.

Croda said all four transactions took place on 11 September, on the London Stock Exchange.

At 1434 BST, shares in Mears Group were down 0.36% at 275p, while those in Croda International were off 2.06% at 5,036p.

Reporting by Josh White for Sharecast.com.

Top Director Buys

Mears Group (MER) Director name: Clarke,Jim Amount purchased: 30,000 @ 275.64p Value: £82,692.00

Lindsell Train Inv Trust (LTI) Director name: MacLellan ,David Amount purchased: 75 @ 90,000.00p Value: £67,500.00

Merit Group (MRIT) Director name: Beck,David Amount purchased: 40,786 @ 49.00p Value: £19,985.14

Cranswick (CWK) Director name: Bottomley,Mark Amount purchased: 576 @ 3,451.00p Value: £19,877.76

Croda International (CRDA) Director name: Brophy ,Tom Amount purchased: 384 @ 5,157.83p Value: £19,806.07

Sylvania Platinum Ltd (di) (SLP) Director name: Reynolds,Adrian J. Amount purchased: 20,000 @ 80.40p Value: £16,080.00

Bp (BP.) Director name: Auchincloss,Murray Amount purchased: 73 @ 517.30p Value: £377.63

Bp (BP.) Director name: Looney,Bernard Amount purchased: 60 @ 517.30p Value: £310.38

Zotefoams (ZTF) Director name: Stirling,David Amount purchased: 44 @ 345.00p Value: £151.80

Easyjet (EZJ) Director name: Jarvis,Kenton Amount purchased: 35 @ 432.00p Value: £151.20

Team17 Group (TM17) Director name: Crawford ,Mark Amount purchased: 44 @ 340.00p Value: £149.60

Zotefoams (ZTF) Director name: McGrath ,Gary Amount purchased: 43 @ 345.00p Value: £148.35

Unilever (ULVR) Director name: Pitkethly,Graeme Amount purchased: 3 @ 4,017.00p Value: £120.51

Top Director Sells

Croda International (CRDA) Director name: Brophy ,Tom Amount sold: 2,250 @ 5,157.83p Value: £116,051.18

Cranswick (CWK) Director name: Bottomley,Mark Amount sold: 580 @ 3,451.00p Value: £20,015.80

Share this article

Related Sharecast Articles

Director dealings: Blue Coast raises stake in Everyman Media
(Sharecast News) - Everyman Media revealed on Thursday that Blue Coast had acquired 50,000 ordinary shares in the AIM-listed cinema group.
Director dealings: Angus Energy CEO ups stake
(Sharecast News) - Angus Energy revealed on Wednesday that chief executive Richard Herbert had acquired 5.0m ordinary shares in the AIM-listed onshore oil and gas development firm.
Director dealings: Abrdn CEO makes share sale
(Sharecast News) - Abrdn revealed on Monday that chief executive Stephen Bird had disposed of 29,942 ordinary shares in the FTSE 250-listed global investment company.
Director dealings: Redx Pharma CEO ups stake
(Sharecast News) - Redx Pharma revealed on Friday that chief executive Lisa Anson had acquired 399,000 ordinary shares in the AIM-listed clinical-stage biopharmaceutical firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.